Nectin Therapeutics Announces Extended Series A Financing To Over $25M And Initiation Of Patient Dosing In Phase 1 Clinical Trial Of Ntx1088, First-In-Class Anti-Pvr Targeted Immunotherapy For Treatment Of Patients With Advanced Solid Tumors
Round Type
Series A
JerusalemBiotechnologyHealth CareTherapeuticsInvestors
Description
Nectin Therapeutics Ltd., (Nectin) a biotechnology company developing novel targeted immunotherapies to address resistance to approved immuno-oncology (IO) treatments, announced today dosing of the first patient in its Phase 1 clinical trial of NTX1088, Nectin's first-in-class PVR (CD155) blocker, in cancer patients with locally advanced and metastatic solid tumors. The trial is being conducted at The University of Texas MD Anderson Cancer Center (MD Anderson) with an investment from the Cancer Focus Fund, LP. The trial will include up to 90 patients treated with NTX1088 as a monotherapy and in combination with a PD-1 blocker.
Quick answer
Nectin Therapeutics raised an undisclosed amount in a Series A round, dated November 30, 2022. Investors: A Moon Fund, Peregrine Ventures, The Cancer Focus Fund and New Investor Israel Biotech Fund. Nectin Therapeutics is based in Jerusalem, Jerusalem District, Israel.
- How much did Nectin Therapeutics raise?
- Nectin Therapeutics raised an undisclosed amount in a Series A round on November 30, 2022.
- Who invested in Nectin Therapeutics?
- A Moon Fund, Peregrine Ventures, The Cancer Focus Fund and New Investor Israel Biotech Fund are named as investors in this round.
- What does Nectin Therapeutics do?
- Nectin Therapeutics is a biotech company focused on unlocking the power of the immune system.
- Where is Nectin Therapeutics based and how big is it?
- Nectin Therapeutics is based in Jerusalem, Jerusalem District, Israel.
- Who are the decision-makers at Nectin Therapeutics?
- Fundz holds 1 contact at Nectin Therapeutics, including the Chief Executive Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Nectin Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- MPC Therapeutics raised an undisclosed amount (Seed) on January 11, 2023.
- Liquidia raised an undisclosed amount (Debt Financing) on January 9, 2023.
- Inotrem raised an undisclosed amount (Funding Round) on January 9, 2023.
- Synthekine raised $100M (Series C) on January 6, 2023.
- HighTide Therapeutics raised $107M (Series C) on January 5, 2023.
- Immune-Onc Therapeutics raised an undisclosed amount (Series B) on January 5, 2023.
Who to call at Nectin Therapeutics, and when
A new round usually means Nectin Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Nectin Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nectin Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nectin Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Nectin Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansNectin Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.